Table 3 Biotechnology companies working on the drugs against host targets and virus-host protein-protein interations
From: Virus-host interactomics: new insights and opportunities for antiviral drug discovery
Company | Web site | Location | Viral application | Stage | Mode of action |
|---|---|---|---|---|---|
Inhikibase Therapeutics | www.inhibikase.com | Atlanta (GA, USA) | Polyomaviruses, HCV, HBV, smallpox virus, ebola virus, RSV, rhinovirus | NC | NC |
Forge Life Science | Doyleston (PA, USA) | JCV, BKV, CMV, seasonal flu | Research | Enhances the innate role of human sirtuins | |
Ciclofilin Pharmaceuticals | San Diego (CA, USA) | HCV/HBV/HIV co-infection | Preclinical | Inhibitors of cyclophilin | |
Gemmus Pharma | San Francisco (CA, USA) | FLUAV | NC | Agonist of a G protein-coupled receptor | |
Springbank Pharmaceuticals | Milford (MA, USA) | HCV and HBV | Phase 1 | Activates RIG1 and NOD2 | |
iTherX | San Diego (CA, USA) | HCV (liver transplant) | Phase 1 | Entry inhibitors | |
Prosetta Biosciences | San Francisco (CA, USA) | HCV, FLUAV, HIV1, RABV | SAR | Targets viral capsid host protein interaction | |
OyaGen Inc | Rochester (NY, USA) | HIV1 | Pre-clinical | APOBEC3G activation and Vif-APOBEC3G interaction | |
Microbiotix | Worcester (MA, USA) | Ebola virus | Discovery | Targets NPC1-glycoprotein interaction | |
Enyo Pharma | Lyon (France) | HBV, FLUAV, Ebola virus | Lead optimization | NC | |
Scynexis | Durham (NC, USA) | HCV | Phase 2 | Inhibitors of cyclophilin | |
Vectura | Germany and UK | Severe FLUAV | Phase 2 | Inhibitor of NF-κB | |
Novartis | Multinational | HCV | Phase 2 and 3 | Cyclophilin A-NS5A interaction |